Corient Private Wealth
ONCT

Corient Private Wealth’s Oncternal Therapeutics, Inc. Common Stock ONCT Stock Holding History

Corient Private Wealth’s Portfolio ONCT Stock Details ONCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-4,579
Closed -$27.5K – 2369
2023
Q3 		$27.5K Sell
4,579
-1,631
-26% -$11.5K ﹤0.01% 2100
2023
Q2 		$42.8K Sell
6,210
-1,313
-17% -$8.66K ﹤0.01% 2026
2023
Q1 		$118K Hold
7,523
– – ﹤0.01% 1866
2022
Q4 		$150K Buy
+7,523
New +$150K ﹤0.01% 1525

Other funds holding ONCT

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PPW
Pasadena Private Wealth Pasadena, California $723M AUM 18.72% 1-Year Est. Return
RB
Richmond Brothers Jackson, Michigan $150M AUM 14.02% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
LPL Financial
LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
IC
IEQ Capital Foster City, California $21.5B AUM 75.26% 1-Year Est. Return

Corient Private Wealth's ONCT Position: Q4 2023 in Review

Corient Private Wealth sold out of Oncternal Therapeutics, Inc. Common Stock (ONCT) in Q4 2023, closing a stake of 4,579 shares — an estimated $27.5K sold.

Corient Private Wealth first reported a position in ONCT in Q4 2022 and held it in 4 quarters. The position peaked at $150K in Q4 2022. 38 funds tracked by Wall St. Rank hold ONCT as of Q4 2023.

  • Corient Private Wealth reported no remaining Oncternal Therapeutics, Inc. Common Stock position as of Q4 2023 after selling out during the quarter.
  • Corient Private Wealth sold 4,579 Oncternal Therapeutics, Inc. Common Stock shares in Q4 2023, an estimated $27.5K.
  • Corient Private Wealth first reported a position in Oncternal Therapeutics, Inc. Common Stock in Q4 2022 and held it in 4 quarters.
  • Corient Private Wealth's Oncternal Therapeutics, Inc. Common Stock position peaked at $150K in Q4 2022.
  • 38 funds tracked by Wall St. Rank held Oncternal Therapeutics, Inc. Common Stock as of Q4 2023.

Based on Corient Private Wealth's 13F filing for Q4 2023, filed 9 Feb 2024.